Bristol Sprycel pricing
Bristol-Myers Squibb is positioning its chronic myeloid leukemia therapy Sprycel (dasatinib) as a less expensive option than high-dose Gleevec (imatinib) for second-line use in Gleevec failures. Sprycel became available within days of its June 28 accelerated approval at a price of $3,900 for a month of treatment at the recommended dosage of 140 mg/day, according to Bristol (1"The Pink Sheet" July 3, 2006, p. 5). In clinical trials, median duration of dasatinib therapy ranged from 2.8 months for lymphoid blast to 5.6 months for CML; the CML trial is ongoing. The company is detailing its multiple tyrosine kinase inhibitor to oncologists and hematologists; the oncology sales force, which has fewer than 200 reps, also details Erbitux (cetuximab)...
You may also be interested in...
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.